Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 101.00K | 101.00K | 101.50K | 101.50K | 101.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.00K | 101.00K | 101.50K | 101.50K | 101.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 101.00K | 101.00K | 101.50K | 101.50K | 101.00K |
| SG&A Expenses | 713.00K | 713.00K | 798.00K | 798.00K | 1.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.44M | 2.44M | 2.63M | 2.63M | 2.55M |
| Operating Income | -2.34M | -2.34M | -2.53M | -2.53M | -2.45M |
| Income Before Tax | -2.30M | -2.30M | -2.48M | -2.48M | -2.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.30M | -2.30M | -2.48M | -2.48M | -2.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.30M | -2.30M | -2.48M | -2.48M | -2.44M |
| EBIT | -2.34M | -2.34M | -2.53M | -2.53M | -2.45M |
| EBITDA | -2.34M | -2.34M | -2.53M | -2.53M | -2.44M |
| EPS Basic | -0.62 | -0.62 | -1.15 | -1.15 | -2.14 |
| Normalized Basic EPS | -0.39 | -0.39 | -0.72 | -0.72 | -1.34 |
| EPS Diluted | -0.62 | -0.62 | -1.15 | -1.15 | -2.14 |
| Normalized Diluted EPS | -0.39 | -0.39 | -0.72 | -0.72 | -1.34 |
| Average Basic Shares Outstanding | 3.71M | 3.71M | 2.16M | 2.16M | 1.14M |
| Average Diluted Shares Outstanding | 3.71M | 3.71M | 2.16M | 2.16M | 1.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |